

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra  
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family

## searching

NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option

NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts

NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

## NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:46:58 ON 08 JUN 2008

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 12:47:21 ON 08 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Jun 2008 VOL 148 ISS 24  
FILE LAST UPDATED: 6 Jun 2008 (20080606/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s SLC and estrone-3-sulfate  
2572 SLC  
54 SLCS  
2603 SLC  
(SLC OR SLCS)  
16657 ESTRONE  
233 ESTRONES  
16734 ESTRONE  
(ESTRONE OR ESTRONES)  
7267544 3  
556133 SULFATE  
100451 SULFATES  
605638 SULFATE  
(SULFATE OR SULFATES)  
317 ESTRONE-3-SULFATE  
(ESTRONE(W)3(W)SULFATE)  
L1 3 SLC AND ESTRONE-3-SULFATE

=> d L1 bib abs 1-3

L1 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:656830 CAPLUS  
DN 147:109041  
TI Scintillation proximity assay for measuring uptake by the human drug  
transporters hOCT1, hOAT3, and hOATP1B1  
AU Lohmann, Christina; Gelius, Birgitta; Danielsson, Jeanette;  
Skoging-Nyberg, Ulrica; Hollnack, Evelyn; Dudley, Adam; Wahlberg, Johanna;  
Hoogstraate, Janet; Gustavsson, Lena  
CS Discovery DMPK and B, AstraZeneca R&D Lund, Lund, 22187, Swed.  
SO Analytical Biochemistry (2007), 366(2), 117-125  
CODEN: ANBCA2; ISSN: 0003-2697  
PB Elsevier  
DT Journal  
LA English  
AB Increasing evidence suggests a key role of transport proteins in the  
pharmacokinetics of drugs. Within the solute carrier (SLC)  
family, various org. cation transporters (OCTs), org. anion transporters

(OATs), and org. anion transporting polypeptides (OATPs) that interact with drug mols. have been identified. Traditionally, cellular uptake assays require multiple steps and provide low exptl. throughput. We here demonstrate the use of a scintillation proximity approach to detect substrate uptake by human drug transporters in real time. HEK293 cells stably transfected with hOCT1, hOATP1B1, or hOAT3 were grown directly in Cytostar-T scintillating microplates. Confluent cell monolayers were incubated with <sup>14</sup>C- or <sup>3</sup>H-labeled transporter substrates. Cellular uptake brings the radioisotopes into proximity with the scintillation plate base. The resulting light emission signals were recorded online in a microplate scintillation counter. Results show time- and concn.-dependent uptake of <sup>14</sup>C-tetraethylammonium, <sup>3</sup>H-methylphenylpyridinium (HEK-hOCT1), <sup>3</sup>H-estradiol-17. $\beta$ .--glucuronide (HEK-hOATP1B1), and <sup>3</sup>H-estrone -3-sulfate (HEK-hOAT3), while no resp. uptake was detected in empty vector-transfected cells. Km of <sup>14</sup>C-tetraethylammonium and <sup>3</sup>H-estrone-3-sulfate uptake and hOAT3 inhibition by ibuprofen and furosemide were similar to conventional dish uptake studies. The scintillation proximity approach is high throughput, amenable to automation and allows for identification of SLC transporter substrates and inhibitors in a convenient and reliable fashion, suggesting its broad applicability in drug discovery.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:65572 CAPLUS

DN 146:288646

TI Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta

AU Grube, Markus; Reuther, Sebastian; dMeyer zu Schwabedissen, Henriette; Koeck, Kathleen; Draber, Katrin; Ritter, Christoph A.; Fusch, Christoph; Jedlitschky, Gabriele; Kroemer, Heyo K.

CS Research Center of Pharmacology and Experimental Therapeutics, Department of Pharmacology, Ernst-Moritz-Arndt-University, Greifswald, Germany

SO Drug Metabolism and Disposition (2007), 35(1), 30-35

CODEN: DMDSAI; ISSN: 0090-9556

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB The human placenta has both protective and nurturing functions for the fetal organism. Uptake and elimination of xenobiotics and endogenous substances are facilitated by various transport proteins from the solute carrier (SLC) and ABC families, resp. A functional interaction of uptake and elimination, which is a prerequisite for vectorial transport

across cellular barriers, has not been described for placenta. In this study, we examd. expression of org. anion transporter (OAT) 4 (SLC22A11), org. anion transporting polypeptide (OATP) 2B1 (SLCO2B1, OATP-B), and breast cancer resistance protein (BCRP) (ABCG2) in human placenta (n = 71) because all three proteins are involved in transmembranal transfer of estrone 3 sulfate (E3S; metabolic product) and dehydroepiandrosterone sulfate (DHEAS; precursor mol.). On the mRNA level, we found a significant correlation of OATP2B1 and BCRP ( $R^2 = 0.534$ ;  $p < 0.01$ ) but not between OAT4 and BCRP ( $R^2 = -0.104$ ;  $p > 0.05$ ). Localization studies confirmed basal expression of OATP2B1 and apical expression of BCRP. To study functional interactions between OATP2B1 and BCRP, we developed a Madin-Darby canine kidney cell model expressing both transport proteins simultaneously (OATP2B1 and BCRP in the basal and apical membrane, resp.). Using this cell model in a transwell system resulted in a significantly increased basal to apical transport of both E3S and DHEAS, when both transporters were expressed with no change of transfer in the apical to basal direction. Taken together, these data show the potential for a functional interaction of OATP2B1 and BCRP in transepithelial transport of steroid sulfates in human placenta.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L1 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2004:257350 CAPLUS  
DN 141:101775  
TI Molecular cloning and functional characterization of the bovine (*Bos taurus*) organic anion transporting polypeptide Oatp1a2 (Slco1a2)  
AU Geyer, Joachim; Doring, Barbara; Failing, Klaus; Petzinger, Ernst  
CS Institute of Pharmacology and Toxicology, Justus-Liebig-University of Giessen, Giessen, D-35392, Germany  
SO Comparative Biochemistry and Physiology, Part B: Biochemistry & Molecular Biology (2004), 137B(3), 317-329  
CODEN: CBPBB8; ISSN: 1096-4959  
PB Elsevier  
DT Journal  
LA English  
AB We describe the cloning, functional characterization and tissue localization of a novel membrane transporter of the OATP/Oatp-gene family obtained from liver and kidney of cattle (*Bos taurus*). The carrier protein exhibits highest sequence identity to the human OATP1A2 (previously called OATP-A) and is, therefore, named bovine Oatp1a2. Bovine Oatp1a2 received the gene symbol Slco1a2 that is identical to the SLC classification of human OATP1A2 (SLCO1A2, previously called SLC21A3) and is likely an orthologue of the human gene. Two different full-length bOatp1a2 cDNAs of 2316-bp and 3504-bp were obtained and

encoded for a 666 amino acid membrane protein, which contains twelve putative transmembrane spanning domains. Bovine Oatp1a2 expression was detected in liver, kidney, brain and adrenal gland. Uptake studies in cRNA-injected oocytes demonstrated that bOatp1a2 transports estrone-3-sulfate and taurocholate, with Km values of 9.6 .mu.M and 51 .mu.M, resp., and estradiol-17.beta.-glucuronide. However, the structurally-related heart glycosides ouabain (1 .mu.M) and digoxin (1 .mu.M) are neither transported by bovine Oatp1a2 nor by human OATP1A2. We conclude that based on the tested substrates bovine Oatp1a2 shows functional homol. to human OATP1A2.

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s estrone-3-sulfate and (breast or mammary)

16657 ESTRONE  
233 ESTRONES  
16734 ESTRONE  
(ESTRONE OR ESTRONES)  
7267544 3  
556133 SULFATE  
100451 SULFATES  
605638 SULFATE  
(SULFATE OR SULFATES)  
317 ESTRONE-3-SULFATE  
(ESTRONE(W)3(W)SULFATE)  
86916 BREAST  
732 BREASTS  
87143 BREAST  
(BREAST OR BREASTS)  
102410 MAMMARY  
18 MAMMARIES  
102416 MAMMARY  
(MAMMARY OR MAMMARIES)  
L2 50 ESTRONE-3-SULFATE AND (BREAST OR MAMMARY)

=> s L2 and transport

787052 TRANSPORT  
6766 TRANSPORTS  
789804 TRANSPORT  
(TRANSPORT OR TRANSPORTS)  
L3 23 L2 AND TRANSPORT

=> s L3 and (cancer or tumor or tumour or carcinoma or malignancy)

361761 CANCER

53214 CANCERS  
375146 CANCER  
    (CANCER OR CANCERS)  
454333 TUMOR  
169801 TUMORS  
506652 TUMOR  
    (TUMOR OR TUMORS)  
11220 OT  
1570 OTS  
12748 OT  
    (OT OR OTS)  
3758 TUMOUR  
1424 TUMOURS  
5093 TUMOUR  
    (TUMOUR OR TUMOURS)  
0 TUMOR OT TUMOUR  
    (TUMOR(W)OT(W)TUMOUR)  
182701 CARCINOMA  
34813 CARCINOMAS  
172 CARCINOMATA  
191024 CARCINOMA  
    (CARCINOMA OR CARCINOMAS OR CARCINOMATA)  
18215 MALIGNANCY  
18670 MALIGNANCIES  
34041 MALIGNANCY  
    (MALIGNANCY OR MALIGNANCIES)  
L4       21 L3 AND (CANCER OR TUMOR OT TUMOUR OR CARCINOMA OR  
MALIGNANCY)

=> duplicate remove L4

PROCESSING COMPLETED FOR L4

L5       21 DUPLICATE REMOVE L4 (0 DUPLICATES REMOVED)

=> d L5 bib abs 1-21

L5 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:255700 CAPLUS

DN 148:302874

TI Method for determining transport activity of a transport  
protein using scintillation proximity assay technology and membrane  
vesicles harboring a C-terminus exposed protein

IN Cui, Yunhai

PA Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim  
Pharma G.m.b.H. & Co. K.-G.

SO PCT Int. Appl., 36pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008022956	A1	20080228	WO 2007-EP58473	20070815
			W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
EP 1892530	A1	20080227	EP 2006-119511	20060825
			R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU	

PRAI EP 2006-119511 A 20060825

AB A single-tube method is provided which allows a fast and waste-sparing method for detg. transport activity of a transport protein and which addnl. is suitable in high-throughput screening (HTS) as well as in ultra-HTS campaigns for the identification of compds. which can modulate transport activity. A basis for the present invention is the finding that a very C-terminal (i.e., 1 up to 25 amino acids) of a transport protein can be markers (e.g., with a histidine tag) and/or targeted (e.g., with an antibody or antibody fragment) without rendering its transport activity. Thereby, the C-terminus can be used as an anchor in an assay for detg. the activity of the transport protein. A further basis is the well known homogeneous and generic assay technol. called scintillation proximity assay (SPA) technol. Thus, membrane vesicles harboring a transport protein with the C-terminus outside and bound to SPA beads is contacted with a radioactively-labeled substrate which is allowed to be transported into the vesicles. Transport activity is measured, by the light emitted by scintillation of the SPA beads.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:1334438 CAPLUS

DN 148:4480

TI Test systems for ABC transporter proteins using cholesterol loaded insect cell membrane

IN Bathori, Gyoergy; Mehn, Dora; Pal, Akos; Krajcsi, Peter; Szente, Lajos; Fenyvesi, Eva; Telbisz, Agnes; Sarkadi, Balazs; Varadi, Andras; Gedey, Szilvia; Glavinas, Hristos; Kis, Emese; Nagy, Tuende; Nemeth, Attila; Molnar, Eva

PA Solvo Biotechnology, Hung.

SO PCT Int. Appl., 56pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007132279	A2	20071122	WO 2007-HU41	20070514
WO 2007132279	A3	20080103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
HU 2006000408	A2	20080228	HU 2006-408	20060512
PRAI HU 2006-408	A	20060512		
HU 2006-754	A	20060927		
AB The invention provides for a novel cholesterol loaded insect cell membrane prepn. having an increased cholesterol level as compared to physiol. cholesterol levels of insect cell membranes or to control insect cell membrane preps. without cholesterol loading, wherein said cholesterol loaded membrane prepn. comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preps. of the invention. The invention also relates to methods for manufg. said preps. and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compds. and interaction of compds. and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane. The				

transport of drugs and other compds. by the ABCG2 and BSEP transporters and interaction of compds. was detd.

L5 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1199713 CAPLUS

DN 148:51353

TI Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma

AU Muto, Mitsuhsia; Onogawa, Tohru; Suzuki, Takashi; Ishida, Takanori; Rikiyama, Toshiki; Katayose, Yu; Ohuchi, Noriaki; Sasano, Hironobu; Abe, Takaaki; Unno, Michiaki

CS Divisions of Gastroenterological Surgery, Tohoku University Graduate School of Medicine, Sendai, 980-8574, Japan

SO Cancer Science (2007), 98(10), 1570-1576

CODEN: CSACCM; ISSN: 1347-9032

PB Blackwell Publishing Asia Pty Ltd.

DT Journal

LA English

AB Human liver-specific org. anion transporter-2 (LST-2/OATP8/SLCO1B3) was demonstrated to be expressed in various gastrointestinal carcinomas and also to play pivotal roles in the uptake of a wide variety of both endogenous and exogenous anionic compds., including bile acids, conjugated steroids and hormones, into hepatocytes in the human liver. However, the biol. significance of LST-2 in human carcinomas remains unknown. In the present study, the authors examd. the expression of LST-2 in 102 cases of breast carcinoma using immunohistochem. and correlated the findings with various clinicopathol. parameters to examine the possible biol. and clin. significance of LST-2. LST-2 immunoreactivity was detected in 51 cases (50.0%); of these 51 pos. cases, LST-2 immunoreactivity was inversely correlated with tumor size ( $P = 0.0289$ ). In addn., LST-2 immunoreactivity was significantly assocd. with a decreased risk of recurrence and improved prognosis by both univariate ( $P = 0.02$  and  $P = 0.01$ ) and multivariate ( $P = 0.03$  and  $P = 0.01$ ) analyses. In the estrogen receptor-pos. groups, the LST-2-pos. patients showed good prognoses. Considering that LST-2 transports estrone-3-sulfate, these results suggest that LST-2 overexpression is assocd. with a hormone-dependent growth mechanism of the breast cancer . The results of the authors' present study demonstrate that LST-2 immunoreactivity is a potent prognostic factor in human breast cancer.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:976904 CAPLUS

DN 147:314075

TI ABCG2 (breast cancer resistance protein/mitoxantrone  
resistance-associated protein) ATPase assay: a useful tool to detect  
drug-transporter interactions

AU Glavinas, Hristos; Kis, Emese; Pal, Akos; Kovacs, Rita; Jani, Marton;  
Vagi, Erika; Molnar, Eva; Bansaghi, Szava; Kele, Zoltan; Janaky, Tamas;  
Bathori, Gyorgy; von Richter, Oliver; Koomen, Gerrit-Jan; Krajcsi, Peter

CS SOLVO Biotechnology, Central Hungarian Innovations Center, Budaors, Hung.

SO Drug Metabolism and Disposition (2007), 35(9), 1533-1542

CODEN: DMDSAI; ISSN: 0090-9556

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB The ATPase assay using membrane preps. from recombinant baculovirus-infected Spodoptera frugiperda ovarian (Sf9) cells is widely used to detect the interaction of compds. with different ATP-binding cassette transporters. However, Sf9 membrane preps. contg. the wild-type ABCG2 transporter show an elevated baseline vanadate-sensitive ATPase activity, which cannot be further stimulated by substrates of ABCG2. Therefore, this assay system cannot be used for the detection of ABCG2 substrates. To overcome this difficulty we (1) purified membranes from a selected human cell line expressing wild-type ABCG2, and (2) inhibited the baseline ATPase activity with different inhibitors. In our modified assay, ABCG2 substrates were able to stimulate the baseline ATPase activity of ABCG2 expressed in membranes of human cells. Furthermore, using the specific ABCG2 inhibitors Ko143 or Ko134 allowed us to suppress the baseline vanadate-sensitive ATPase activity. Substrates of ABCG2 could stimulate this suppressed baseline ATPase, resulting in a better signal-to-background ratio and a robust assay to detect substrates of the ABCG2 transporter. The ATPase assay and the direct vesicular transport measurements for estrone-3-sulfate were in good accordance.

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:407458 CAPLUS

DN 146:372197

TI Interactions of cyclosporin A with breast cancer  
resistance protein

AU Xia, Cindy Q.; Liu, Ning; Miwa, Gerald T.; Gan, Liang-Shang

CS Drug Metabolism and Pharmacokinetics, Drug Safety and Disposition,  
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA

SO Drug Metabolism and Disposition (2007), 35(4), 576-582

CODEN: DMDSAI; ISSN: 0090-9556

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB The objective of this study was to investigate whether cyclosporin A (CsA) is a modulator for breast cancer resistance protein (BCRP). The interactions between CsA and BCRP were evaluated by using both membrane- and cell-based assays. CsA inhibited BCRP or BCRP R482T mutant-assocd. ATPase with an IC<sub>50</sub> of 26.1 and 7.3 .mu.M (31,388 and 8779 ng/mL), resp., indicating that CsA is a modulator for BCRP and its R482T mutant. The apparent permeability (Papp) of CsA was not affected by the BCRP-specific inhibitor Ko143 in both apical-to-basolateral (A-to-B) and basolateral-to-apical (B-to-A) directions in hBCRP- or mBcrp-transfected MDCKII cells, whereas CsA at 50 .mu.M significantly increased the A-to-B transport and decreased B-to-A transport of BCRP substrates, [<sup>3</sup>H]estrone-3-sulfate ([<sup>3</sup>H]E3S) and [<sup>3</sup>H]methotrexate ([<sup>3</sup>H]MTX), in hBCRP- and mBcrp1-transfected MDCKII cells. Similar to cellular transport studies, CsA did not exhibit ATP-dependent uptake in BCRP-expressed membrane vesicles but inhibited the ATP-mediated E3S and MTX uptake in the same vesicles. The inhibitory const. (Ki) of CsA toward BCRP was 6.7 .mu.M (8507 ng/mL) and 7.8 .mu.M (9380 ng/mL) when using E3S or MTX, resp., as a BCRP substrate. The inhibitory potency of CsA on BCRP wild type or its R482T mutant was lower than that on P-glycoprotein. The present studies demonstrate that CsA is an inhibitor but not a substrate for BCRP, and has low potential to cause drug-drug interactions with BCRP substrate drugs due to its weak inhibitory effect on BCRP and BCRP R482T mutant at its normal therapeutic blood concns. (200-400 ng/mL).

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:65572 CAPLUS

DN 146:288646

TI Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta

AU Grube, Markus; Reuther, Sebastian; dMeyer zu Schwabedissen, Henriette; Koeck, Kathleen; Draber, Katrin; Ritter, Christoph A.; Fusch, Christoph; Jedlitschky, Gabriele; Kroemer, Heyo K.

CS Research Center of Pharmacology and Experimental Therapeutics, Department of Pharmacology, Ernst-Moritz-Arndt-University, Greifswald, Germany

SO Drug Metabolism and Disposition (2007), 35(1), 30-35

CODEN: DMDSAI; ISSN: 0090-9556

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB The human placenta has both protective and nurturing functions for the fetal organism. Uptake and elimination of xenobiotics and endogenous substances are facilitated by various transport proteins from the solute carrier (SLC) and ABC families, resp. A functional interaction of uptake and elimination, which is a prerequisite for vectorial transport across cellular barriers, has not been described for placenta. In this study, we examd. expression of org. anion transporter (OAT) 4 (SLC22A11), org. anion transporting polypeptide (OATP) 2B1 (SLCO2B1, OATP-B), and breast cancer resistance protein (BCRP) (ABCG2) in human placenta (n = 71) because all three proteins are involved in transmembranal transfer of estrone 3 sulfate (E3S; metabolic product) and dehydroepiandrosterone sulfate (DHEAS; precursor mol.). On the mRNA level, we found a significant correlation of OATP2B1 and BCRP ( $R^2 = 0.534$ ;  $p < 0.01$ ) but not between OAT4 and BCRP ( $R^2 = -0.104$ ;  $p > 0.05$ ). Localization studies confirmed basal expression of OATP2B1 and apical expression of BCRP. To study functional interactions between OATP2B1 and BCRP, we developed a Madin-Darby canine kidney cell model expressing both transport proteins simultaneously (OATP2B1 and BCRP in the basal and apical membrane, resp.). Using this cell model in a transwell system resulted in a significantly increased basal to apical transport of both E3S and DHEAS, when both transporters were expressed with no change of transfer in the apical to basal direction. Taken together, these data show the potential for a functional interaction of OATP2B1 and BCRP in transepithelial transport of steroid sulfates in human placenta.

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1123248 CAPLUS

DN 145:449189

TI Inhibitory agent for estrone-3-sulfate transporter activity

IN Tamai, Ikumi; Yabuuchi, Hikaru

PA Genomembrane Co., Ltd., Japan

SO PCT Int. Appl., 30pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.      KIND    DATE      APPLICATION NO.      DATE

----- ----- ----- ----- -----

PI WO 2006112330 A1 20061026 WO 2006-JP307751 20060412  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KN, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,  
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,  
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,  
YU, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

JP 2006298781 A 20061102 JP 2005-119098 20050415  
PRAI JP 2005-119098 A 20050415

AB Disclosed is an agent for inhibiting the transporter activity of an estrone-3-sulfate transporter, an agent for inhibiting the growth of breast cancer cells, or an agent for the treatment of breast cancer, which does not need to be incorporated in cells, has excellent drug delivery property and has few side effects. The agent comprises at least one component selected from genistein, quercetin, ginkgolide C, theaflavin, theaflavin 3-o-gallate, chalcone, rutin, daidzein, daidzin, flavanone, flavonol, geraldol, hesperetin, hespereridine, ipriflavone, luteolin-7-o-glucoside, methoxychalcone, 4'-methyl-7-methoxy-isoflavone, 5-morin, myricetin, naringenin, naringenin-7-glycoside, naringin, neoheesperidin dihydrochalcone, nomilin, primuletin, poncirin, scutellarein, catechin hydrate, and chem. modified products thereof.

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:652528 CAPLUS

DN 145:96426

TI Inhibitors of estrone 3-sulfate transporter  
and application as the inhibitors for breast cancer  
cell proliferation and anti-breast cancer drugs

IN Tamai, Ikumi; Nozawa, Takashi; Yabuuchi, Hikaru

PA Geno Membrane K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 26 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

-----  
PI JP 2006176427 A 20060706 JP 2004-370290 20041221  
PRAI JP 2004-370290 20041221

AB The inhibitor mixts. for estrone 3-sulfate

transporter activity contg. bromosulfophthalein (BSP) as a major component and .gtoreq.1 component selected from , dehydroepiandrosterone sulfate, dehydroepiandrosterone, taurocholic acid, p-aminohippuric acid, tetraethylammonium, probenecid, and benzylpenicillin as active ingredients have been developed. BSP (at 30 and 100 .mu.M) inhibited the estrone 3-sulfate-dependent proliferation of human breast cancer MCF-7 cells (ATCC-HTB22). The inhibitor mixts. can be used as anti-breast cancer drugs.

L5 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:429496 CAPLUS

DN 144:485144

TI Lack of Interaction between Tauroursodeoxycholate and ATP-Binding Cassette Transporter Isoform G2 (ABCG2)

AU Vaidya, Soniya S.; Gerk, Phillip M.

CS Department of Pharmaceutics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA, 23298, USA

SO Molecular Pharmaceutics (2006), 3(3), 303-306

CODEN: MPOHBP; ISSN: 1543-8384

PB American Chemical Society

DT Journal

LA English

AB Ursodiol (UDCA) is useful for treating several cholestatic hepatic maladies, including intrahepatic cholestasis of pregnancy. Its taurine amide (TUDC), which accumulates in the bile salt pool, could interact with ABCG2 (ATP-binding cassette transporter isoform G2), which is expressed in various tissues including the canalicular membrane of the hepatocyte and in the apical membrane of the placental syncytiotrophoblast. The purpose of this study was to det. the interaction between TUDC and ABCG2. ABCG2 was expressed in Sf9 cells, and ABCG2-mediated ATP-dependent transport was detd. in sucrose-fractionated Sf9 membrane vesicles. The transport of estrone 3-sulfate (E1S) into ABCG2-expressing membranes was ATP-dependent and was much greater in membrane vesicles expressing ABCG2 vs. the neg. control (empty virus lacking the ABCG2 coding region). To det. whether TUDC affects ABCG2-mediated ATP-dependent transport of E1S, transport activity in the presence of TUDC (20-500 .mu.M) was measured. No significant changes were obsd. in the ABCG2-mediated ATP-dependent E1S transport. Furthermore, ABCG2-mediated TUDC transport was undetectable. Thus, TUDC does not affect ABCG2-mediated E1S transport and is not an ABCG2

substrate.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1034579 CAPLUS

DN 143:359639

TI Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells

AU Nozawa, Takashi; Suzuki, Masato; Yabuuchi, Hikaru; Irokawa, Masanori; Tsuji, Akira; Tamai, Ikumi

CS Department of Molecular Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba, 278-8510, Japan

SO Pharmaceutical Research (2005), 22(10), 1634-1641

CODEN: PHREEB; ISSN: 0724-8741

PB Springer Science+Business Media, Inc.

DT Journal

LA English

AB The aim of the study is to suppress the progress of estrogen-dependent breast cancer by inhibiting the membrane transporter, which mediates the internalization of estrone-3-sulfate as estrogen precursor in the cancer cells. The uptake of estrone-3-sulfate by estrogen-dependent breast cancer MCF-7 cells was measured, and inhibitory study using various org. anions on estrone-3-sulfate uptake by MCF-7 cells was conducted. The effects of the inhibitor on the transcription of reporter gene and cell proliferation induced by estrone-3-sulfate were examined. The uptake of estrone-3-sulfate by MCF-7 cells was saturable with Km value of 2.32 .mu.M. The uptake was Na+-independent and was inhibited by several anionic compds. such as bromosulfophthalein. Bromosulfophthalein also significantly inhibited the transcription of reporter gene via estrogen response element and cell proliferation induced by estrone-3-sulfate. However, the transcriptional activation or cell proliferation induced by estrone was not inhibited by bromosulfophthalein. Reverse transcription-polymerase chain reaction anal. revealed the expression of mRNA of org. anion transporting polypeptide (OATP)-D and OATP-E as possible candidates to transport estrone-3-sulfate. The uptake of estrone-3-sulfate is mediated by Na+-independent transporter(s). Inhibitor of estrone-3-sulfate transporter suppressed the transcription and cell proliferation induced by estrone-3-sulfate

in MCF-7 cells. The results provide the basis of a novel strategy for breast cancer treatment by focusing on the transporter responsible for the uptake of estrone-3-sulfate.

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:990907 CAPLUS

DN 143:318322

TI Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein

AU Matsushima, Soichiro; Maeda, Kazuya; Kondo, Chihiro; Hirano, Masaru; Sasaki, Makoto; Suzuki, Hiroshi; Sugiyama, Yuichi

CS Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

SO Journal of Pharmacology and Experimental Therapeutics (2005), 314(3), 1059-1067

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB Until recently, it was generally believed that the transport of various org. anions across the bile canalicular membrane was mainly mediated by multidrug resistance-assoccd. protein 2 (MRP2/ABCC2). However, a no. of new reports have shown that some org. anions are also substrates of multidrug resistance 1 (MDR1/ABCB1) and/or breast cancer resistance protein (BCRP/ABCG2), implying MDR1 and BCRP could also be involved in the biliary excretion of org. anions in humans. In the present study, we constructed new double-transfected Madin-Darby canine kidney II (MDCKII) cells expressing org. anion-transporting polypeptide 1B1 (OATP1B1)/MDR1 and OATP1B1/BCRP, and we investigated the transcellular transport of four kinds of org. anions, estradiol-17.beta.-D-glucuronide (EG), estrone-3-sulfate (ES), pravastatin (PRA), and cerivastatin (CER), to identify which efflux transporters mediate the biliary excretion of compds. using double-transfected cells. We obsd. the vectorial transport of EG and ES in all the double transfectants. MRP2 showed the highest efflux clearance of EG among these efflux transporters, whereas BCRP-mediated clearance of ES was the highest in these double transfectants. In addn., two kinds of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, CER and PRA, were also substrates of all these

efflux transporters. The rank order of the efflux clearance of PRA mediated by each transporter was the same as that of EG, whereas the contribution of MDR1 to the efflux of CER was relatively greater than for PRA. This exptl. system is very useful for identifying which transporters are involved in the biliary excretion of org. anions that cannot easily penetrate the plasma membrane.

L5 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:424553 CAPLUS  
DN 143:41311  
TI Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells  
AU Xia, Cindy Q.; Liu, Ning; Yang, David; Miwa, Gerald; Gan, Liang-Shang  
CS Drug Metabolism and Pharmacokinetics, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA  
SO Drug Metabolism and Disposition (2005), 33(5), 637-643  
CODEN: DMDSAI; ISSN: 0090-9556  
PB American Society for Pharmacology and Experimental Therapeutics  
DT Journal  
LA English  
AB The function of breast cancer resistance protein (BCRP) and its role in drug absorption, distribution, and elimination has recently been evaluated. The objective of the present study was to examine the expression, localization, and functional characteristics of BCRP in Caco-2 cells, a widely used human intestinal epithelial cell model for investigating intestinal drug absorption. The expression of BCRP in Caco-2 cells was measured by Western blotting using the antibody BXP-21. Localization of BCRP was detd. by an immunofluorescence technique using both antibodies BXP-21 and BXP-34. The drug efflux function of BCRP was evaluated via the epithelial transport of methotrexate (MTX) and estrone-3-sulfate (E3S) across Caco-2 cell monolayers in the presence or absence of the BCRP inhibitors Ko143 or GF120918 (N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide). Results from Western blot assay indicated that Caco-2 cells in the late passage (p56) expressed a higher level of BCRP as compared with the level in the early passages (p33). The total amt. of BCRP protein did not change after the cells were confluent. Immunofluorescence studies revealed the pos. staining of BCRP on the apical membrane of Caco-2 cells but not on the basolateral membrane after cell confluence. MTX and E3S showed a preferential basolateral-to-apical (B-to-A) transport across Caco-2 cell monolayers. Both BCRP inhibitors Ko143 and GF120918 increased the apical-to-basolateral (A-to-B) transport but decreased the B-to-A transport of MTX and E3S. Caco-2 cells may therefore be used as an in vitro model to study the transport characteristics of BCRP.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:537945 CAPLUS

DN 143:70898

TI Role of the breast cancer resistance protein (ABCG2)  
in drug transport

AU Mao, Qingcheng; Unadkat, Jashvant D.

CS Department of Pharmaceutics, School of Pharmacy, University of Washington,  
Seattle, WA, 98195, USA

SO AAPS Journal (2005), 7(1), E118-E133

CODEN: AJAOB6; ISSN: 1550-7416

URL: <http://www.aapsj.org/articles/aapsj0701/aapsj070112/aapsj070112.pdf>

PB American Association of Pharmaceutical Scientists

DT Journal; General Review; (online computer file)

LA English

AB A review. The 72-kDa breast cancer resistance protein (BCRP) is the second member of the subfamily G of the human ATP binding cassette (ABC) transporter superfamily and thus also designated as ABCG2. Unlike P-glycoprotein and MRP1, which are arranged in 2 repeated halves, BCRP is a half-transporter consisting of only 1 nucleotide binding domain followed by 1 membrane-spanning domain. Current exptl. evidence suggests that BCRP may function as a homodimer or homotetramer. Overexpression of BCRP is assocd. with high levels of resistance to a variety of anticancer agents, including anthracyclines, mitoxantrone, and the camptothecins, by enhancing drug efflux. BCRP expression has been detected in a large no. of hematol. malignancies and solid tumors, indicating that this transporter may play an important role in clin. drug resistance of cancers. In addn. to its role to confer resistance against chemotherapeutic agents, BCRP actively transports structurally diverse org. mols., conjugated or unconjugated, such as estrone-3-sulfate, 17.beta.-estradiol 17-(.beta.-D-glucuronide), and methotrexate. BCRP is highly expressed in the placental syncytiotrophoblasts, in the apical membrane of the epithelium in the small intestine, in the liver canalicular membrane, and at the luminal surface of the endothelial cells of human brain microvessels. This strategic and substantial tissue localization indicates that BCRP also plays an important role in absorption, distribution, and elimination of drugs that are BCRP substrates. This review summarizes current knowledge of BCRP and its relevance to multidrug resistance and drug disposition.

RE.CNT 140 THERE ARE 140 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:861947 CAPLUS

DN 142:215577

TI Functional analysis of SNPs variants of BCRP/ABCG2

AU Kondo, Chihiro; Suzuki, Hiroshi; Itoda, Masaya; Ozawa, Shogo; Sawada, Jun-ichi; Kobayashi, Daisuke; Ieiri, Ichiro; Mine, Kazunori; Ohtsubo, Kenji; Sugiyama, Yuichi

CS School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, 113-0033, Japan

SO Pharmaceutical Research (2004), 21(10), 1895-1903

CODEN: PHREEB; ISSN: 0724-8741

PB Springer Science+Business Media, Inc.

DT Journal

LA English

AB The aim of the current study was to identify the effect of single nucleotide polymorphisms (SNPs) in breast cancer resistance protein (BCRP/ABCG2) on its localization, expression level, and transport activity. The cellular localization was identified using the wild type and seven different SNP variants of BCRP (V12M, Q141K, A149P, R163K, Q166E, P269S, and S441N BCRP) after transfection of their cDNAs in plasmid vector to LLC-PK1 cells. Their expression levels and transport activities were detd. using the membrane vesicles from HEK293 cells infected with the recombinant adenoviruses contg. these kinds of BCRP cDNAs. Wild type and six different SNP variants of BCRP other than S441N BCRP were expressed on the apical membrane, whereas S441N BCRP showed intracellular localization. The expression levels of Q141K and S441N BCRP proteins were significantly lower compared with the wild type and the other five variants. Furthermore, the transport activity of E1S, DHEAS, MTX, and PAH normalized by the expression level of BCRP protein was almost the same for the wild type, V12M, Q141K, A149P, R163K, Q166E, and P269S BCRP. These results suggest that Q141K SNPs may assoc. with a lower expression level, and S441N SNPs may affect both the expression level and cellular localization. It is possible that subjects with these polymorphisms may have lower expression level of BCRP protein and, consequently, a reduced ability to export these substrates.

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:752061 CAPLUS

DN 141:307179

TI Gefitinib reverses breast cancer resistance protein-mediated drug resistance

AU Yanase, Kae; Tsukahara, Satomi; Asada, Sakiyo; Ishikawa, Etsuko; Imai, Yasuo; Sugimoto, Yoshikazu

CS Division of Molecular Biotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research and Department of Chemotherapy, Kyoritsu University of Pharmacy, Tokyo, Japan

SO Molecular Cancer Therapeutics (2004), 3(9), 1119-1125

CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research

DT Journal

LA English

AB Breast cancer resistance protein (BCRP) is an ATP

binding cassette transporter that confers resistance to a series of anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), topotecan, and mitoxantrone. In this study, we evaluated the possible interaction of gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, with BCRP. BCRP-transduced human epidermoid carcinoma A431 (A431/BCRP) cells acquired cellular resistance to gefitinib, suggesting that BCRP could be one of the determinants of gefitinib sensitivity in a certain sort of cells. Next, the effect of gefitinib on BCRP-mediated drug resistance was examined. Gefitinib reversed SN-38 resistance in BCRP-transduced human myelogenous leukemia K562 (K562/BCRP) or BCRP-transduced murine lymphocytic leukemia P388 (P388/BCRP) cells but not in these parental cells. In addition, gefitinib sensitized human colon cancer HT-29 cells, which endogenously express BCRP, to SN-38. Gefitinib increased intracellular accumulation of topotecan in K562/BCRP cells and suppressed ATP-dependent transport of estrone 3-sulfate, a substrate of BCRP, in membrane vesicles from K562/BCRP cells. These results suggest that gefitinib may overcome BCRP-mediated drug resistance by inhibiting the pump function of BCRP. Furthermore, P388/BCRP-transplanted mice treated with combination of irinotecan and gefitinib survived significantly longer than those treated with irinotecan alone or gefitinib alone. In conclusion, gefitinib is shown to interact with BCRP. BCRP expression in a certain sort of cells is supposed to be one of the determinants of gefitinib sensitivity. Gefitinib inhibits the transporter function of BCRP and reverses BCRP-mediated drug resistance both in vitro and in vivo.

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:1065635 CAPLUS

DN 142:17254

TI Involvement of estrone-3-sulfate  
transporters in proliferation of hormone-dependent breast  
cancer cells

AU Nozawa, Takashi; Suzuki, Masato; Takahashi, Koichi; Yabuuchi, Hikaru;

Maeda, Tomoji; Tsuji, Akira; Tamai, Ikumi  
CS Department of Molecular Biopharmaceutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan  
SO Journal of Pharmacology and Experimental Therapeutics (2004), 311(3), 1032-1037  
CODEN: JPETAB; ISSN: 0022-3565  
PB American Society for Pharmacology and Experimental Therapeutics  
DT Journal  
LA English  
AB Although circulating estrone-3-sulfate is a major precursor of biol. active estrogen, permeation across the plasma membrane is unlikely to occur by diffusion because of the high hydrophilicity of the mol. The object of this study was to clarify the involvement of specific transporter(s) in the supply of estrone-3-sulfate to human breast cancer -derived T-47D cells, which grow in an estrogen-dependent manner. The proliferation of T-47D cells was increased by the addn. of estrone-3-sulfate, or estradiol, to the cultivation medium.  
The initial uptake rate of estrone-3-sulfate kinetically exhibited a single saturable component, with Km and Vmax values of 7.6 .mu.M and 172 pmol/mg of protein/min, resp. The replacement of extracellular Na+ with Li+, K+, or N-methylglucamine+ had no effect on the uptake of [3H]estrone-3-sulfate. The uptake was strongly inhibited by sulfate conjugates of steroid hormones, but not by estradiol-17.beta.-glucuronide. Taurocholate and sulfobromophthalein inhibited the uptake, whereas other tested anionic and cationic compds. did not. The expression of org. anion transporting polypeptides, OATP-D and OATP-E, which are candidate transporters of estrone-3-sulfate, was detected by reverse transcription-polymerase chain reaction anal., although their actual involvement in the uptake of estrogen remains to be clarified. In conclusion, the uptake of estrone-3-sulfate by T-47D cells was mediated by a carrier-mediated transport mechanism, suggesting that the estrogen precursor is actively imported by estrogen-dependent breast cancer cells.

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2004:542898 CAPLUS  
DN 141:224038  
TI Functional expression of the human breast cancer resistance protein in Pichia pastoris  
AU Mao, Qingcheng; Conseil, Gwenaelle; Gupta, Anshul; Cole, Susan P. C.; Unadkat, Jashvant D.

CS Department of Pharmaceutics, School of Pharmacy, University of Washington,  
Seattle, WA, 98195, USA

SO Biochemical and Biophysical Research Communications (2004), 320(3),  
730-737

CODEN: BBRCA9; ISSN: 0006-291X

PB Elsevier Science

DT Journal

LA English

AB We report functional expression of BCRP in *Pichia pastoris* in which BCRP was produced as a 62 kDa underglycosylated protein. BCRP expression level in *P. pastoris* was comparable to that in HEK cells. The basal BCRP ATPase activity in the yeast membranes was approx. 40-80 nmol Pi/min/mg protein, which can be modulated by known BCRP substrates and inhibitors.

Photolabeling of BCRP with 8-azido[.alpha.-32P]ATP was dependent preferentially on the presence of Co<sup>2+</sup> than Mg<sup>2+</sup> and could be inhibited by a molar excess of ATP. Vanadate-induced trapping of 8-azido[.alpha.-32P]ADP by BCRP was much more significant in the presence of Co<sup>2+</sup> than that with Mg<sup>2+</sup>. The Km and Vmax values of BCRP for [<sup>3</sup>H]E1S transport were 3.6 .+-. 0.3 .mu.M and 55.2 .+-. 1.6 pmol/min/mg protein, resp. This efficient and cost-effective expression system should facilitate large scale prodn. and purifn. of BCRP for further structural and functional analyses.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:459152 CAPLUS

DN 139:192696

TI ABCG2 Transports Sulfated Conjugates of Steroids and Xenobiotics

AU Suzuki, Michiko; Suzuki, Hiroshi; Sugimoto, Yoshikazu; Sugiyama, Yuichi

CS School of Pharmaceutical Sciences, The University of Tokyo, Hongo,

Bunkyo-ku, Tokyo, 113-0033, Japan

SO Journal of Biological Chemistry (2003), 278(25), 22644-22649

CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB The mechanism for the cellular extrusion of sulfated conjugates is still unknown. In the present study, we investigated whether human wild type ABCG2 transports estrone 3-sulfate (E1S) using membrane vesicles from cDNA-transfected mouse lymphoma cell line (P388 cells). The uptake of [<sup>3</sup>H]E1S into ABCG2-expressing membrane vesicles was stimulated by ATP, and the Km value for [<sup>3</sup>H]E1S was detd. to be 16.6 .mu.M. The ABCG2-mediated transport of [<sup>3</sup>H]E1S was

potently inhibited by SN-38 and many sulfate conjugates but not by

glucuronide and glutathione conjugates or other anionic compds. Other sulfate conjugates such as [<sup>3</sup>H]dehydroepiandrosterone sulfate (DHEAS) and [<sup>35</sup>S]4-methylumbelliferone sulfate ( $K_m = 12.9 \text{ }\mu\text{M}$ ) and [<sup>35</sup>S]6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole (E3040) sulfate ( $K_m = 26.9 \text{ }\mu\text{M}$ ) were also transported by ABCG2. Although [<sup>3</sup>H]methotrexate, [<sup>3</sup>H]17. $\beta$ -estradiol-17. $\beta$ -D-glucuronide, [<sup>3</sup>H]2,4-dinitrophenyl-S-glutathione, and [<sup>14</sup>C]4-methylumbelliferone glucuronide were transported by ABCG2, this took place to a much lesser extent compared with [<sup>3</sup>H]E1S. It was suggested that ABCG2 preferentially transports sulfate conjugates and that E1S and DHEAS are the potential physiol. substrates for this transporter.

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:657783 CAPLUS

DN 139:358994

TI Identification of steroid sulfate transport processes in the human mammary gland

AU Pizzagalli, F.; Varga, Z.; Huber, R. D.; Folkers, G.; Meier, P. J.; St-Pierre, M. V.

CS Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital of Zuerich, Zurich, 8091, Switz.

SO Journal of Clinical Endocrinology and Metabolism (2003), 88(8), 3902-3912  
CODEN: JCEMAZ; ISSN: 0021-972X

PB Endocrine Society

DT Journal

LA English

AB Circulating hormones and local biotransformation of steroid precursors are both sources of estrogen in human mammary tissue.

Estrone-3-sulfate (E1S) is an important estrogenic form in premenopausal women, and dehydroepiandrosterone sulfate (DHEAS) constitutes a major adrenal precursor. Membrane transport systems that govern delivery of these anionic steroid conjugates to the mammary gland were investigated. RNA was screened by RT-PCR and Northern blotting for expression of org. anion transporting polypeptide (OATP) (solute carrier family 21A) and org. anion transporter (OAT) (solute carrier family 22A) gene families. OATP-B (SLC21A9) was the major carrier expressed; OATP-D (SLC21A11) and OATP-E (SLC21A12) were less abundant. In normal sections, OATP-B immunolocalized to the myoepithelium that surrounds the ductal epithelial cells. In invasive carcinoma, ductal epithelial cells were pos. OATP-B was characterized in stable transfected Chinese hamster ovary cells. E1S affinity const. ( $K_m$ ) is 5  $\mu\text{mol/L}$ , max. velocity ( $V_{max}$ ) is 777 pmol/mg.cntdot.min and  $K_m$  for DHEAS is 9  $\mu\text{mol/L}$ ,  $V_{max}$  is 85 pmol/mg.cntdot.min. The prostaglandins (PG) A1

and PGA2 stimulated uptake of E1S and DHEAS by increasing Vmax 2-fold but not changing Km. The effect of PGA was selectively blocked by the lipophilic thiol reagent N-ethylmaleimide but not by the hydrophilic acetamido-4'(iodoacetyl)aminostilbene-2,2'-disulfonic acid, suggesting an interaction between the electrophilic cyclopentenone ring and specific cysteine residues of OATP-B.

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:88107 CAPLUS

DN 139:4099

TI Transport of sulfated conjugates by human breast cancer resistance protein (BCRP/ABCG2)

AU Suzuki, Michiko; Suzuki, Hiroshi; Sugiyama, Yuichi; Sugimoto, Yoshikazu

CS Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan

SO Japanese Pharmacology & Therapeutics (2002), 30(Suppl. 2), S433-S436

CODEN: JPTABU

PB Raifu Saiensu Shuppan K.K.

DT Journal

LA Japanese

AB The uptake of estrone 3-sulfate (E1S) was obsd. in the BCRP protein-contg. membrane vesicles in the presence of ATP. The E1S uptake was not affected in the presence of glutathione conjugates and glucuronate conjugates, but was suppressed in the presence of sulfate conjugates. The BCRP protein-contg. membrane vesicles also taken up org. anions, such as DHEA sulfate and 4-methylumbelliflferone sulfate in the presence of ATP and relatively low uptake of MTX, Estradiol-17.beta.-D-glucuronide, and DNP-SG. Apparently, BCRP may be involved in the transport of E1S and other sulfate conjugates.

L5 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:795665 CAPLUS

DN 132:30824

TI Pharmaceutical composition with tumor necrosis factor-.alpha. or other biological response modifier and 2-methoxyestrone-3-O-sulphamate for inhibition of estrone sulphatase and treatment of cancer

IN Reed, Michael John; Potter, Barry Victor Lloyd

PA Sterix Limited, UK

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 14

PATENT NO.      KIND   DATE      APPLICATION NO.      DATE

-----  
PI WO 9964013 A1 19991216 WO 1999-GB1835 19990610  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
CA 2334119 A1 19991216 CA 1999-2334119 19990610  
AU 9942807 A 19991230 AU 1999-42807 19990610  
AU 765386 B2 20030918  
EP 1085876 A1 20010328 EP 1999-955428 19990610  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI  
JP 2002517449 T 20020618 JP 2000-553081 19990610  
AU 726811 B2 20001123 AU 2000-10130 20000106  
US 6676934 B1 20040113 US 2000-724986 20001128  
AU 769753 B2 20040205 AU 2001-23181 20010222  
US 20040127473 A1 20040701 US 2003-674892 20030930  
PRAI GB 1998-12535 A 19980610  
GB 1999-10167 A 19990430  
GB 1996-25334 A 19961205  
WO 1997-GB3352 A2 19971204  
US 1998-111927 A2 19980708  
AU 1999-10077 A 19990111  
WO 1999-GB1835 W 19990610  
US 1999-319213 A2 19991123  
AU 2000-10130 A3 20000106  
US 2000-724986 A2 20001128

OS MARPAT 132:30824

AB The compn. comprises a sulfamate compd., e.g. 2-methoxyestrone-3-O-sulfamate, and a biol. response modifier, e.g., TNF. The compn. is useful for the prevention and/or treatment of cancer.

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT